國立虎尾科技大學 |

Regulation of Cancer Immune Checkpoints = Molecular and Cellular Mechanisms and Therapy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Regulation of Cancer Immune Checkpoints/ edited by Jie Xu.
其他題名:	Molecular and Cellular Mechanisms and Therapy /
其他作者:	Xu, Jie.
面頁冊數:	X, 653 p. 105 illus., 57 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Molecular Medicine. -
電子資源:	https://doi.org/10.1007/978-981-15-3266-5
ISBN:	9789811532665

Regulation of Cancer Immune Checkpoints = Molecular and Cellular Mechanisms and Therapy /
Regulation of Cancer Immune CheckpointsMolecular and Cellular Mechanisms and Therapy /[electronic resource] :edited by Jie Xu. - 1st ed. 2020. - X, 653 p. 105 illus., 57 illus. in color.online resource. - Advances in Experimental Medicine and Biology,12480065-2598 ;. - Advances in Experimental Medicine and Biology,889.

Introduction -- Molecular and cellular functions of CTLA-4 pathway -- Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond -- Discovery of new immune checkpoints: family grows up -- Mechanisms of resistance to checkpoint blockade therapy -- Molecular events behind adverse effects -- Rational discovery of response biomarkers -- Spatiotemporal changes in checkpoint molecule expression -- Functions of checkpoint molecules beyond immune evasion -- Genetic alterations and checkpoint expression -- Regulations on messenger RNA: wires and nodes -- Folded or degraded in endoplasmic reticulum -- Mono- and poly-ubiquitination: tags for fates -- Lysosome as the black hole for checkpoint molecules -- Phosphorylation: a fast switch for checkpoint signalling -- Palmitoylation as a signal for delivery -- Checkpoints under traffic control: from and to organelles -- Exosome and secretion: action on? -- Macromolecules and antibody-based drugs -- Mechanisms inspired targeting peptides -- Small molecular inhibitors -- Therapeutic development of immune checkpoint blockers -- Concluding remarks.

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.

ISBN: 9789811532665

Standard No.: 10.1007/978-981-15-3266-5doiSubjects--Topical Terms:

668353
Molecular Medicine.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Regulation of Cancer Immune Checkpoints = Molecular and Cellular Mechanisms and Therapy /
LDR:04213nam a22004095i 4500 001 1022783
003 DE-He213
005 20200703135101.0
007 cr nn 008mamaa
008 210318s2020 si | s |||| 0|eng d
020 $a 9789811532665 $9 978-981-15-3266-5
024 7 $a 10.1007/978-981-15-3266-5 $2 doi
035 $a 978-981-15-3266-5
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Regulation of Cancer Immune Checkpoints $h [electronic resource] : $b Molecular and Cellular Mechanisms and Therapy / $c edited by Jie Xu.
250 $a 1st ed. 2020.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2020.
300 $a X, 653 p. 105 illus., 57 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 1248
505 0 $a Introduction -- Molecular and cellular functions of CTLA-4 pathway -- Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond -- Discovery of new immune checkpoints: family grows up -- Mechanisms of resistance to checkpoint blockade therapy -- Molecular events behind adverse effects -- Rational discovery of response biomarkers -- Spatiotemporal changes in checkpoint molecule expression -- Functions of checkpoint molecules beyond immune evasion -- Genetic alterations and checkpoint expression -- Regulations on messenger RNA: wires and nodes -- Folded or degraded in endoplasmic reticulum -- Mono- and poly-ubiquitination: tags for fates -- Lysosome as the black hole for checkpoint molecules -- Phosphorylation: a fast switch for checkpoint signalling -- Palmitoylation as a signal for delivery -- Checkpoints under traffic control: from and to organelles -- Exosome and secretion: action on? -- Macromolecules and antibody-based drugs -- Mechanisms inspired targeting peptides -- Small molecular inhibitors -- Therapeutic development of immune checkpoint blockers -- Concluding remarks.
520 $a This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
650 2 4 $a Molecular Medicine. $3 668353
650 1 4 $a Cancer Research. $3 668358
650 0 $a Molecular biology. $3 583443
650 0 $a Immunology. $3 592892
650 0 $a Cancer research. $3 1253664
700 1 $a Xu, Jie. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1318563
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811532658
776 0 8 $i Printed edition: $z 9789811532672
776 0 8 $i Printed edition: $z 9789811532689
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-981-15-3266-5
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)